

HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

error, please notify the sender immediately to arrange for the return of this document

Sapropterin Dihydrochloride

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:		
HPP Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Patient Primary Phone:		NPI:	PA PROMISe ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Line of Business: Medicaid CHIP		Specialty Pharmacy (if applicable):		
Drug Name:		Strength:		
Quantity:		Refills:		
Directions:				
Diagnosis Code:	Diagnosis:			
HPP's maximum approval time is 12 months but may be less depending on the drug.				

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.			
Q1. Is this a request for a renewal? If YE	S, go to 9.		
Yes	□ No		
Q2. Is the request for brand name Kuvan	?		
🗌 Yes	□ No		
Q3. Is Sapropterin Dihydrochloride being prescribed by or in consultation with a metabolic diseases specialist or a provider who specializes in the treatment of PKU?			
☐ Yes	□ No		
Q4. Does the patient have a diagnosis of phenylketonuria confirmed by blood phenylalanine concentrations? Chart notes documenting diagnosis AND labs must be attached.			
☐ Yes	□ No		
Q5. Has the patient tried non-pharmacological treatment options (such as restriction of dietary phenylalanine intake)? Notes must be attached showing the patient has tried and failed dietary restriction in consultation with a nutritionist.			
☐ Yes	□ No		
Q6. Is there documentation that Sapropterin Dihydrochloride will be used in combination with a Phe-restricted diet? Notes must be attached documenting patient is following a Phe-restricted diet in consultation with a nutritionist.			
🗌 Yes	□ No		
Q7. Is there documentation showing the patient has tried generic Sapropterin Dihydrochloride for at least one month and has not achieved at least a 20% reduction in blood phenylalanine concentration from baseline at a max dose of			
entity named above. The authorized recipient of this informat	belonging to the sender that is legally privileged. This information is intended only for the use of the individual or ion is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are stion taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in		



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Sapropterin Dihydrochloride

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:		
20mg/kg/day or documentation of contraindication/intolerance to generic? Labs must be attached.			
☐ Yes	□ No		
Q8. Will this drug be used in combination with Palynziq?			
☐ Yes	□ No		
Q9. Has the patient been previously approved for treatment?			
☐ Yes	□ No		
Q10. Has the patient been compliant with filling their prescription?			
☐ Yes	□ No		
Q11. Has the patient experienced any serious side effects including esophagitis or gastritis?			
☐ Yes	□ No		
Q12. Has the patient had at least a 20% reduction in blood phenylalanine concentration from baseline after at least 2 months of therapy at a max dose of 20mg/kg/day? Labs must be attached.			
☐ Yes	□ No		
Q13. Is this drug being used in combination with Palynziq	?		
☐ Yes	□ No		
Q14. Additional Information:			

Prescriber Signature

Date

Updated for 2023